Technical Data
T5050-12
Thrombopoietin, Recombinant, Mouse (TPO, Mpl-ligand, MGDF)
2ug
10ug
10ug
|
Technical Data |
|
T5050-12 |
Thrombopoietin, Recombinant, Mouse (TPO, Mpl-ligand, MGDF) |
2ug 10ug |
| Molecular Biology | Storage: -20°CShipping: RT |
|
Recombinant Murine TPO is a single, non-glycosylated soluble polypeptide chain containing 174 amino acids and having a molecular mass of 18.7kD which comprises the receptor binding domain of the Mpl-ligand protein. Sequence : The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Pro-Val-Ala-Pro. Biological Activity: Recombinant TPO is fully biologically active when compared to standard. The ED50 as determined by the dose-dependent stimulation of MO7e cells is less then 1 ng/ml, corresponding to a Specific Activity of 1x10e6 IU/mg. Storage and Stability: Lyophilized powder may be stored at -20°C. Reconstitute to nominal volume by adding sterile ddH2O, 0.1% HSA or BSA. Aliquot and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: 18.7kD |
Source: E. coli Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Concentration: ~0.1mg/ml Form: Supplied as a lyophilized powder. No additives. Reconstitute with sterile ddH2O, 0.1% HSA or BSA to a concentration of 100ug/ml, which can then be further diluted to other aqueous solutions. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Thrombopoietin induces HOXA9 nuclear transport in immature hematopoietic cells: potential mechanism by which the hormone favorably affects hematopoietic stem cells. Kirito K, Fox N, Mol Cell Biol 2004 Aug;24(15):6751-62 2. Synergistic effects on erythropoiesis, thrombopoiesis, and stem cell competitiveness in mice deficient in thrombopoietin and steel factor receptors. Antonchuk J, Hyland CD, Alexander WS, Blood 2004 Sep 1;104(5):1306-13 3. A functional erythropoietin receptor is necessary for the action of thrombopoietin on erythroid cells lacking c-mpl. Rouleau C, Cui K, Exp Hematol 2004 Feb;32(2):140-8 4. Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Carpinelli MR, Hilton DJ, Antonchuk JL, Hilton AA, Proc Natl Acad Sci U S A 2004 Apr 27;101(17):6553-8 5. Hematopoietic-repopulating defects from STAT5-deficient bone marrow are not fully accounted for by loss of thrombopoietin responsiveness. Bradley HL, Couldrey C, Blood 2004 Apr 15;103(8):2965-72 6. Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities. Inagaki K, Oda T, Shinkai H, Blood 2004 Jul 1;104(1):58-64.
|
||